GlassScriptPhysician profile
Tam Tran
NPI 1366124356
$1,565.39
in general payments reported to CMS, 2019-2025
24 companies · $770 in 2025
The $770 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $795 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $211.30 | 2024-2025 | Farxiga, Airsupra |
| Eisai INC. | $136.83 | 2024-2025 | |
| Novo Nordisk INC | $113.75 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $110.51 | 2024-2025 | |
| Lilly USA, LLC | $107.79 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Corcept Therapeutics | $89.72 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $85.39 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $75.62 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $64.63 | 2024-2025 | |
| Ibsa Pharma INC. | $62.28 | 2024-2025 | Flector, Tirosint, Licart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.02 | 2024-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $55.87 | 2024 | Trintellix |
| Merck Sharp & Dohme LLC | $52.44 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Avvisto Therapeutics, LLC | $45.56 | 2024-2025 | Cycloset |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.65 | 2024-2025 | Xifaxan, Trulance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $40.34 | 2025 | Vyepti |
| Axsome Therapeutics, INC. | $40.17 | 2025 | Auvelity |
| Dynavax Technologies Corporation | $34.12 | 2024-2025 | Heplisav-B |
| Glaxosmithkline, LLC. | $32.94 | 2025 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $30.28 | 2025 | Gemtesa |
| Inari Medical, INC. | $20.25 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $19.39 | 2024 | |
| Seqirus USA INC | $18.14 | 2024 | Flucelvax, Fluad |
| Phathom Pharmaceuticals, INC. | $15.40 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tam Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.